Global Cancer Biomarker Market Revenue Expected To Reach $52.63 Billion By 2030

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Cancer Biomarker Market Compare Between 2026 And 2030?

The cancer biomarker market size has experienced rapid growth in recent years. It is projected to expand from $25.09 billion in 2025 to $29.07 billion by 2026, reflecting a compound annual growth rate (CAGR) of 15.9%. Historically, this expansion has been driven by factors such as the increasing global prevalence of cancer, advancements in molecular biology research, increased funding for oncology research, the rising adoption of diagnostics based on biomarkers, and improvements in imaging and assay technologies.

The cancer biomarker market is poised for significant expansion in the coming years, with its valuation expected to climb to $52.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.0%. This projected growth throughout the forecast period stems from factors such as the increasing need for personalized oncology treatments, growing investments in precision medicine, the broadening scope of biomarker-driven drug development, the rising adoption of AI-based biomarker analysis, and an intensified focus on early-stage cancer screening. Additionally, major developments anticipated during this timeframe encompass the wider application of genetic and protein biomarkers, an increase in the uptake of companion diagnostics, deeper integration of omics technologies, the expansion of liquid biopsy uses, and a reinforced commitment to detecting cancer at its earliest stages.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

What Are The Main Drivers Accelerating The Growth Of The Cancer Biomarker Market?

The increasing occurrence of cancer is a primary factor driving the expansion of the cancer biomarker market. The cancer incidence rate denotes the number of new cancer cases of a specific site or type that arise in a given population annually, expressed as cancers per 100,000 individuals at risk. This escalating incidence of cancer is leading to the extensive utilization of cancer biomarkers because they are instrumental in assessing disease risk, screening for occult primary tumors, distinguishing between benign and malignant indicators, or separating different forms of malignancy. Cancer biomarkers facilitate the early detection, diagnosis, and ongoing monitoring of cancer by indicating the disease’s presence or progression, thereby enabling personalized treatment approaches and improving patient outcomes. For example, in May 2024, a report released by the International Agency for Research on Cancer (IARC), a France-based cancer research organization, revealed that in 2022, approximately 20 million new cancer cases were reported, leading to 9.7 million deaths, and it is projected that by 2050, new cancer cases will exceed 35 million, representing a 77% increase compared to 2022. Therefore, the rising incidence of cancer is anticipated to propel the growth of the cancer biomarker market in the foreseeable future.

How Is Segment Classification Applied In The Cancer Biomarker Market?

The cancer biomarker market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types

2) By Profiling Technologies: Omics Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Biomarker Types: Epigenetic Biomarkers, Metabolomic Biomarkers

What Trends Are Impacting The Cancer Biomarker Market?

Leading companies in the cancer biomarker market are concentrating on developing innovative solutions, such as AI-powered cancer biomarkers, to improve diagnostic accuracy and personalize treatment plans for patients. AI-powered cancer biomarkers are biological indicators of cancer identified and analyzed with artificial intelligence technologies. For example, in September 2023, Ibex Medical Analytics, a US-based company, introduced Galen Breast HER2, an AI-driven solution crafted to boost the accuracy and reproducibility of HER2 scoring in breast cancer patients. This advanced platform supports pathologists by automatically detecting invasive tumor areas and quantifying HER2 expression based on the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system employs a novel computational pipeline to analyze immunohistochemistry (IHC)-stained slides, delivering detailed visualizations of staining patterns and enabling pathologists to make informed treatment decisions.

Which Industry Players Are Present In The Cancer Biomarker Market?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Access The Complete Cancer Biomarker Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Which Region Has The Strongest Presence In The Cancer Biomarker Market?

North America was the largest region in the cancer biomaker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Cancer Biomarker Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

Browse Through More Reports Similar to the Global Cancer Biomarker Market 2026, By The Business Research Company

Calcium Peroxide Market Report 2026

https://www.thebusinessresearchcompany.com/report/calcium-peroxide-global-market-report

Calcium Channel Blocker Market Report 2026

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Calcium Nitrate Market Report 2026

https://www.thebusinessresearchcompany.com/report/calcium-nitrate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795